Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings

Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial.

(2022) Laura Spring et al.   JOURNAL OF CLINICAL ONCOLOGY

LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)

(2022) H.S. Rugo et al.   ANNALS OF ONCOLOGY

Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2022) Hope S. Rugo et al.   JOURNAL OF CLINICAL ONCOLOGY

LBA4 Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase I trial

(2021) A. Bardia et al.   ANNALS OF ONCOLOGY

TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

(2021) Scott T. Tagawa et al.   JOURNAL OF CLINICAL ONCOLOGY

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

(2021) Aditya Bardia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

(2021) A. Bardia et al.   ANNALS OF ONCOLOGY

LBA49 Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study

(2021) E.B. Garon et al.   ANNALS OF ONCOLOGY

O2-1 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: Updated results of TROPION-PanTumor01 phase 1 study*

(2021) Toshio Shimizu et al.   ANNALS OF ONCOLOGY

ImmunoPET of trophoblast cell-surface antigen 2 (Trop-2) expression in pancreatic cancer

(2021) Weiyu Chen et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Datopotamab deruxtecan (Dato-DXd), a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells

(2021) Daisuke Okajima et al.   MOLECULAR CANCER THERAPEUTICS

A first in-human study of A166 in patients with locally advanced/metastatic solid tumors which are HER2-positive or HER2-amplified who did not respond or stopped responding to approved therapies.

(2020) Yongheng Liu et al.   JOURNAL OF CLINICAL ONCOLOGY

Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial

(2020) K. Kalinsky et al.   ANNALS OF ONCOLOGY

A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors

(2018) Gentry T. King et al.   INVESTIGATIONAL NEW DRUGS

The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target

(2018) David M. Goldenberg et al.   Oncotarget

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

(2017) Aditya Bardia et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan

(2017) Rebecca Suk Heist et al.   JOURNAL OF CLINICAL ONCOLOGY

Overexpression of TROP2 promotes proliferation and invasion of ovarian cancer cells

(2017) Bin Wu et al.   Experimental and Therapeutic Medicine

TROP2 promotes proliferation, migration and metastasis of gallbladder cancer cells by regulating PI3K/AKT pathway and inducing EMT

(2017) Xinxing Li et al.   Oncotarget

Correlation between Trop2 and amphiregulin coexpression and overall survival in gastric cancer

(2017) Wei Zhao et al.   Cancer Medicine

Prognostic role and clinical significance of trophoblast cell surface antigen 2 in various carcinomas

(2017) Peng Xu et al.   Cancer Management and Research

Trop-2 Induces Tumor Growth Through AKT and Determines Sensitivity to AKT Inhibitors

(2016) Emanuela Guerra et al.   CLINICAL CANCER RESEARCH

RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models

(2016) P. Strop et al.   MOLECULAR CANCER THERAPEUTICS

Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay

(2016) Jung Wook Park et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis

(2016) Ping Zeng et al.   Scientific Reports

Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers

(2015) Thomas M. Cardillo et al.   BIOCONJUGATE CHEMISTRY

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

(2015) A. N. Starodub et al.   CLINICAL CANCER RESEARCH

Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan)

(2015) R. M. Sharkey et al.   CLINICAL CANCER RESEARCH

Trop2: From development to disease

(2015) Annie R.A. McDougall et al.   DEVELOPMENTAL DYNAMICS

siRNA targeting of Trop2 suppresses the proliferation and invasion of lung adenocarcinoma H460 cells

(2015) XIAO-YAN GAO et al.   Experimental and Therapeutic Medicine

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

(2015) David M. Goldenberg et al.   Oncotarget

Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts

(2015) Marco Trerotola et al.   Oncotarget

Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients

(2015) Nobuyuki Horita et al.   Scientific Reports

Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC

(2015) Kaihua Zhang et al.   Oncotarget

Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications

(2014) Andreas Maderna et al.   JOURNAL OF MEDICINAL CHEMISTRY

Pretargeted ImmunoPET of Prostate Cancer with an Anti-TROP-2 x Anti-HSG Bispecific Antibody in Mice with PC3 Xenografts

(2014) Catharina M. van Rij et al.   MOLECULAR IMAGING AND BIOLOGY

Trop-2 Promotes Prostate Cancer Metastasis By Modulating  1 Integrin Functions

(2013) M. Trerotola et al.   CANCER RESEARCH

Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway

(2013) H Nakanishi et al.   ONCOGENE

Overexpression of TROP2 Predicts Poor Prognosis of Patients with Cervical Cancer and Promotes the Proliferation and Invasion of Cervical Cancer Cells by Regulating ERK Signaling Pathway

(2013) Ting Liu et al.   PLoS One

Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells

(2013) T. Stoyanova et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Biochemical and preliminary X-ray characterization of the tumor-associated calcium signal transducer 2 (Trop2) ectodomain

(2013) Tilen Vidmar et al.   PROTEIN EXPRESSION AND PURIFICATION

TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma

(2012) Jau-Chen Lin et al.   EMBO Molecular Medicine

Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer

(2012) Hong Lin et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Trop-2 inhibits prostate cancer cell adhesion to fibronectin through the β1 integrin-RACK1 axis

(2012) Marco Trerotola et al.   JOURNAL OF CELLULAR PHYSIOLOGY

A New Tri-Fab Bispecific Antibody for Pretargeting Trop-2-Expressing Epithelial Cancers

(2012) R. M. Sharkey et al.   JOURNAL OF NUCLEAR MEDICINE

Upregulation of Trop-2 quantitatively stimulates human cancer growth

(2012) M Trerotola et al.   ONCOGENE

The Trop-2 signalling network in cancer growth

(2012) E Guerra et al.   ONCOGENE

Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys

(2011) T. M. Cardillo et al.   CLINICAL CANCER RESEARCH

Expression of Trop2 Cell Surface Glycoprotein in Normal and Tumor Tissues

(2011) Lara P. Stepan et al.   JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY

Loss of Trop2 Promotes Carcinogenesis and Features of Epithelial to Mesenchymal Transition in Squamous Cell Carcinoma

(2011) J. Wang et al.   MOLECULAR CANCER RESEARCH

New Antibody Conjugates in Cancer Therapy

(2011) Serengulam V. Govindan et al.   TheScientificWorldJOURNAL

Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway

(2010) Rafael Cubas et al.   Molecular Cancer

Cell-autonomous activation of the PI3-kinase pathway initiates endometrial cancer from adult uterine epithelium

(2010) S. Memarzadeh et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of a Cell of Origin for Human Prostate Cancer

(2010) A. S. Goldstein et al.   SCIENCE

Potential hepatic stem cells reside in EpCAM+ cells of normal and injured mouse liver

(2009) M. Okabe et al.   DEVELOPMENT

TROP2 expression as prognostic marker for gastric carcinoma

(2008) G Muhlmann et al.   JOURNAL OF CLINICAL PATHOLOGY

Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers

(2008) J. Wang et al.   MOLECULAR CANCER THERAPEUTICS

Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics

(2008) A. S. Goldstein et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA